The American Academy of Pediatrics advocates for universal childhood flu shots in the 2026-27 season, countering federal policy changes that classify vaccines into shared decision-making categories, highlighting ongoing debates over immunisation strategies and disparities in health outcomes.
The American Academy of Pediatrics is urging routine influenza vaccination for all children aged 6 months and older as it published its 2026-27 seasonal guidance, reinforcing a long-standing recommendation even as federal vaccine policy moves in a different direction. The academy said the updated policy statement and technical report reflect current strain selection, new treatment information and revised advice on prevention and antiviral use ahead of the coming respiratory season.
The timing is striking. On 10 August 2026, President Donald Trump signed an executive order that pushed flu, hepatitis A, hepatitis B, rotavirus and COVID-19 vaccines into a shared decision-making category rather than keeping them on the universal childhood list. The same day, AAP president Andrew D. Racine called the move “not only disheartening but dangerous”, while the academy’s own annual schedule continued to recommend flu vaccination and other routine childhood immunisations.
For this season, the academy says all influenza vaccines licensed in the US are trivalent, meaning they protect against three virus strains, and their composition has been updated to match current World Health Organisation and FDA advice for the northern hemisphere. Afluria is no longer available, and guidance for immunocompromised children has been revised to align more closely with other professional groups. The academy also highlighted a small but measurable increase in fever-related seizures seen in young children after some flu shots, while stressing that the estimated risk remains low.
The AAP continues to recommend that children 9 and older need just one flu dose, while younger children need two doses at least four weeks apart unless they have already had two lifetime doses before the current season. It says vaccination should ideally be completed by the end of October and that any licensed product suitable for a child’s age and health status may be used. That advice comes against a backdrop of weak uptake: according to the academy, just 49.4% of US children ages 6 months to 17 years had been vaccinated by 16 May 2026.
The statement also underscores who is most likely to suffer severe illness. Children under 5, especially those under 2, and those with chronic lung, heart, kidney, liver, blood, metabolic or neurological conditions, or who are immunocompromised, are at greater risk of hospitalisation and complications. The academy said disparities remain stark, with higher rates of flu-related hospital and intensive care admissions among Black, Hispanic and American Indian/Alaska Native children over 10 seasons, and higher in-hospital death rates among Black, Hispanic and Asian/Pacific Islander children than among White children.
On treatment, the AAP recommends starting antivirals quickly for children who are hospitalised, severely ill or at high risk, regardless of vaccination status. Oseltamivir remains its preferred option for influenza A and B. The academy also advises testing when results will change care, including whether to begin antivirals, avoid unnecessary antibiotics or tighten infection-control measures.
The policy shift is already causing friction beyond paediatrics. According to reporting by Drug Topics, the split between the AAP and federal guidance could affect pharmacy workflows, billing and scope of practice because many state rules and insurance policies track the federal immunisation schedule. The academy said the CDC has not yet released its own flu guidance for the coming season, leaving professional groups to rely on their own recommendations for now.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
